C-EDGE.TN Study: Grazoprevir/Elbasvir in Genotype 1, 4, or 6 - Treatment for HCV Infection

The C-EDGE.TN Study evaluated the efficacy of grazoprevir/elbasvir treatment in patients with HCV infection, specifically genotype 1, 4, or 6. The study included 316 patients and aimed to achieve SVR12 rates superior to historical standards. The treatment was well-tolerated, with high SVR12 rates ac

0 views • 9 slides